Epidemiology of non-melanoma skin cancer

Non-Surgical Treatment of Keratinocyte Skin Cancer

Volumn , Issue , 2010, Pages 15-24

  Jensen, Annette Ostergaard ^a   Lamberg, Anna Lei ^a   Olesen, Anne Braae ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84872143018     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-540-79341-0_3     Document Type: Chapter

References (74)

1. Cancer Incidence and Mortality in the Nordic Countries, version 3.1. Association of Nordic Cancer Registries. Danish Cancer Society. Available at http://www.ancr.nu.
2. Harris RB, Griffi th K, Moon TE. Trends in the incidence of nonmelanoma skin cancers in southeastern Arizona, 1985-1996. J Am Acad Dermatol. 2001;45:528-36.
3. Staples MP, Elwood M, Burton RC, Williams JL, Marks R, Giles GG. Non-melanoma skin cancer in Australia: The 2002 national survey and trends since 1985. Med J Aust. 2006;184: 6-10.
4. American Cancer Society. Cancer facts & fi gures, 2007. Available at http://www.cancer.org.
5. de Vries E, Louwman M, Bastiaens M, de Gruijl F, Coebergh JW. Rapid and continuous increases in incidence rates of basal cell carcinoma in the southeast Netherlands since 1973. J Invest Dermatol. 2004;123:634-8.
6. Karagas MR, Greenberg ER, Spencer SK, Stukel TA, Mott LA. Increase in incidence rates of basal cell and squamous cell skin cancer in New Hampshire, USA. New Hampshire Skin Cancer Study Group. Int J Cancer. 1999;81: 555-9.
7. Levi F, Te VC, Randimbison L, Erler G, La Vecchia C. Trends in skin cancer incidence in Vaud: An update, 1976-1998. Eur J Cancer Prev. 2001;10:371-3.
8. Diepgen TL, Mahler V. The epidemiology of skin cancer. Br J Dermatol. 2002;146(Suppl 61):1-6.
9. Gloster HM, J., Brodland DG. The epidemiology of skin cancer. Dermatol Surg. 1996;22:217-26.
10. Hannuksela-Svahn A, Pukkala E, Karvonen J. Basal cell skin carcinoma and other nonmelanoma skin cancers in Finland from 1956 through 1995. Arch Dermatol. 1999;135: 781-6.
11. Staples M, Marks R, Giles G. Trends in the incidence of non-melanocytic skin cancer (NMSC) treated in Australia 1985-1995: Are primary prevention programs starting to have an effect? Int J Cancer. 1998;78:144-8.
12. Green A, Battistutta D, Hart V, Leslie D, Weedon D. Skin cancer in a subtropical Australian population: incidence and lack of association with occupation. The Nambour Study Group. Am J Epidemiol. 1996;144:1034-40.
13. Buettner PG, Raasch BA. Incidence rates of skin cancer in Townsville, Australia. Int J Cancer. 1998;78:587-93.
14. Hoey SE, Devereux CE, Murray L, Catney D, Gavin A, Kumar S, Donnelly D, Dolan OM. Skin cancer trends in Northern Ireland and consequences for provision of dermatology services. Br J Dermatol. 2007;156:1301-7.
15. Athas WF, Hunt WC, Key CR. Changes in nonmelanoma skin cancer incidence between 1977-1978 and 1998-1999 in Northcentral New Mexico. Cancer Epidemiol Biomarkers Prev 2003;12(10):1105-8.
16. Brewster DH, Bhatti LA, Inglis JH, Nairn ER, Doherty VR. Recent trends in incidence of nonmelanoma skin cancers in the East of Scotland, 1992-2003. Br J Dermatol 2007 Jun; 156(6):1295-300.
17. Karagas MR, Weinstock MA, Nelson HH. Keratinocyte carcinomas. In: Schottenfeld FJD (ed) Cancer epidemiology and prevention, third edition. Oxford: Oxford University Press, 2006, pp. 1230-50.
18. Christenson LJ, Borrowman TA, Vachon CM, Tollefson MM, Otley CC, Weaver AL, Roenigk RK. Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA. 2005;294:681-90.
19. Montague M, Borland R, Sinclair C. Slip! Slop! Slap! and SunSmart, 1980-2000: Skin cancer control and 20 years of population-based campaigning. Health Educ Behav. 2001;28: 290-305.
20. Bastiaens MT, Hoefnagel JJ, Bruijn JA, Westendorp RG, Vermeer BJ, Bouwes Bavinck JN. Differences in age, site distribution, and sex between nodular and superfi cial basal cell carcinoma indicate different types of tumors. J Invest Dermatol. 1998;110:880-4.
21. Raasch BA, Buettner PG, Garbe C. Basal cell carcinoma: histological classifi cation and body-site distribution. Br J Dermatol. 2006;155:401-7.
22. Cancer Incidence in fi ve continents, vol. VII. International Agency for Research on Cancer (IARC), Lyon, 1997.
23. Frisch M, Melbye M. New primary cancers after squamous cell skin cancer. Am J Epidemiol. 1995;141:916-22.
24. Frisch M, Hjalgrim H, Olsen JH, Melbye M. Risk for subsequent cancer after diagnosis of basal-cell carcinoma. A population-based, epidemiologic study. Ann Intern Med. 1996; 125:815-21.
25. Bower CP, Lear JT, Bygrave S, Etherington D, Harvey I, Archer CB. Basal cell carcinoma and risk of subsequent malignancies: A cancer registry-based study in southwest England. J Am Acad Dermatol. 2000;42:988-91.
26. Lucke TW, Hole DJ, MacKie RM. An audit of the completeness of non-melanoma skin cancer registration in Greater Glasgow. Br J Dermatol. 1997;137:761-3.
27. Frentz G, Olsen JH. Malignant tumours and psoriasis: A follow-up study . Br J Dermatol. 1999;140:237-42.
28. Magnus K. The Nordic profi le of skin cancer incidence. A comparative epidemiological study of the three main types of skin cancer. Int J Cancer. 1991;47:12-9.
29. Jensen A.Ø. Personal communication. Århus, 2006.
30. Frentz G. General skin cancer. Quantity, treatment and quality. Ugeskr Laeger. 1996;158:7202.
31. Adami HO, Hunter D, Trichopoulos D. Textbook of cancer epidemiology. Oxford: Oxford University Press, 2002, p. 282.
32. Sorensen HT, Sabroe S, Olsen J. A framework for evaluation of secondary data sources for epidemiological research. Int J Epidemiol. 1996;25:435-42.
33. Lewis KG, Weinstock MA. Nonmelanoma skin cancer mortality (1988-2000): The Rhode Island follow-back study. Arch Dermatol. 2004;140:837-42.
34. Weinstock MA. Nonmelanoma skin cancer mortality in the United States, 1969 through 1988. Arch Dermatol. 1993;129: 1286-90.
35. Osterlind A, Hjalgrim H, Kulinsky B, Frentz G. Skin cancer as a cause of death in Denmark. Br J Dermatol. 1991;125:580-2.
36. Weinstock MA, Bogaars HA, Ashley M, Litle V, Bilodeau E, Kimmel S. Nonmelanoma skin cancer mortality. A population-based study. Arch Dermatol. 1991;127:1194-7.
37. Fletcher RW, Fletcher SW. Clinical epidemiology the essentials. Philadelphia, PA: Lippincott Williams & Wilkins, 2005.
38. Sackett DL, Haynes RB, Guyatt GH, Tugwell P. Clinical epidemiology: A basic science for clinical medicine, 2nd ed. Boston, MA: Little, Brown, 1991.
39. Rigel DS, Friedman RJ, Dzubow LM, Reintgen DS, Bystryn J, Marks R. Cancer of the skin, 2nd ed., Philadelphia, PA: Elsevier Saunders, 2005.
40. Robins P, Albom MJ. Recurrent basal cell carcinomas in young women. J Dermatol Surg. 1975;1:49-51.
41. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-83.
42. Ong CS, Keogh AM, Kossard S, MacDonald PS, Spratt PM. Skin cancer in Australian heart transplant recipients. J Am Acad Dermatol. 1999;40:27-34.
43. Jensen AO, Olesen AB, Dethlefsen C, Sorensen HT. Ten year mortality in a cohort of nonmelanoma skin cancer patients in denmark. J Invest Dermatol. 2006; 126:2539-41.
44. Marcil I, Stern RS. Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: A critical review of the literature and meta-analysis. Arch Dermatol. 2000;136:1524-30.
45. Karagas MR, Greenberg ER, Mott LA, Baron JA, Ernster VL. Occurrence of other cancers among patients with prior basal cell and squamous cell skin cancer. Cancer Epidemiol Biomarkers Prev. 1998;7:157-61.
46. Wassberg C, Thorn M, Yuen J, Ringborg U, Hakulinen T. Second primary cancers in patients with squamous cell carcinoma of the skin: A population-based study in Sweden. Int J Cancer. 1999;80, 511-5.
47. Levi F, La Vecchia C, Te VC, Randimbison L, Erler G. Incidence of invasive cancers following basal cell skin cancer. Am J Epidemiol. 1998;147:722-6.
48. Levi F, Randimbison L, La Vecchia C, Erler G, Te VC. Incidence of invasive cancers following squamous cell skin cancer. Am J Epidemiol. 1997;146:734-9.
49. Hjalgrim H, Frisch M, Storm HH, Glimelius B, Pedersen JB, Melbye M. Non-melanoma skin cancer may be a marker of poor prognosis in patients with non-Hodgkin's lymphoma. Int J Cancer. 2000;85:639-42.
50. Nugent Z, Demers AA, Wiseman MC, Mihalcioiu C, Kliewer EV. Risk of second primary cancer and death following a diagnosis of nonmelanoma skin cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:2584-90.
51. Hemminki K, Vaittinen P, Kyyronen P. Age-specifi c familial risks in common cancers of the offspring. Int J Cancer. 1998; 78:172-5.
52. Bouwes Bavinck JN, Feltkamp M, Struijk L, ter Schegget J. Human papillomavirus infection and skin cancer risk in organ transplant recipients. J Investig Dermatol Symp Proc. 2001;6:207-11.
53. Hemminki K, Dong C. Primary cancers following squamous cell carcinoma of the skin suggest involvement of Epstein-Barr virus. Epidemiology. 2000;11:94.
54. Rosenberg CA, Greenland P, Khandekar J, Loar A, Ascensao J, Lopez AM. Association of nonmelanoma skin cancer with second malignancy. Cancer. 2004;100:130-8.
55. Brewster AM, Alberg AJ, Strickland PT, Hoffman SC, Helzlsouer K. XPD polymorphism and risk of subsequent cancer in individuals with nonmelanoma skin cancer. Cancer Epidemiol Biomarkers Prev. 2004;13:1271-5.
56. Adami J, Frisch M, Yuen J, Glimelius B, Melbye M. Evidence of an association between non-Hodgkin's lymphoma and skin cancer. BMJ. 1995;310:1491-5.
57. Karagas MR, Cushing GL Jr, Greenberg ER, Mott LA, Spencer SK, Nierenberg DW. Non-melanoma skin cancers and glucocorticoid therapy. Br J Cancer. 2001;85:683-6.
58. Smedby KE, Hjalgrim H, Melbye M, Torrang A, Rostgaard K, Munksgaard L, Adami J, Hansen M, Porwit-MacDonald A, Jensen BA, Roos G, Pedersen BB, Sundstrom C, Glimelius B, Adami HO. Ultraviolet radiation exposure and risk of malignant lymphomas. J Natl Cancer Inst. 2005;97: 199-209.
59. Grant WB, Holick MF. Benefi ts and requirements of vitamin D for optimal health: A review. Altern Med Rev. 2005;10: 94-111.
60. Tuohimaa P, Pukkala E, Scelo G, Olsen JH, Brewster DH, Hemminki K, Tracey E, Weiderpass E, Kliewer EV, Pompe-Kirn V, McBride ML, Martos C, Chia KS, Tonita JM, Jonasson JG, Boffetta P, Brennan P. Does solar exposure, as indicated by the non-melanoma skin cancers, protect from solid cancers: vitamin D as a possible explanation. Eur J Cancer. 2007;43:1701-12.
61. Gallagher RP, Hill GB, Bajdik CD, Coldman AJ, Fincham S, McLean DI, Threlfall WJ. Sunlight exposure, pigmentation factors, and risk of nonmelanocytic skin cancer. II. Squamous cell carcinoma. Arch Dermatol. 1995a;131:164-9.
62. Gallagher RP, Hill GB, Bajdik CD, Fincham S, Coldman AJ, McLean DI, Threlfall W J. Sunlight exposure, pigmentary factors, and risk of nonmelanocytic skin cancer. I. Basal cell carcinoma. Arch Dermatol. 1995b;131:157-63.
63. Pappas G, Queen S, Hadden W, Fisher G. The increasing disparity in mortality between socioeconomic groups in the United States, 1960 and 1986. N Engl J Med. 1993;329:103-9.
64. Huisman M, Kunst AE, Andersen O, Bopp M, Borgan JK, Borrell C, Costa G, Deboosere P, Desplanques G, Donkin A, Gadeyne S, Minder C, Regidor E, Spadea T, Valkonen T, Mackenbach JP. Socioeconomic inequalities in mortality among elderly people in 11 European populations. J Epidemiol Community Health. 2004;58:468-75.
65. Mackenbach JP, Bos V, Andersen O, Cardano M, Costa G, Harding S, Reid A, Hemstrom O, Valkonen T, Kunst AE. Widening socioeconomic inequalities in mortality in six Western European countries. Int J Epidemiol. 2003;32: 830-7.
66. Charles AJ Jr, Otley CC, Pond GR. Prognostic factors for life expectancy in nonagenarians with nonmelanoma skin cancer: implications for selecting surgical candidates. J Am Acad Dermatol. 2002;47:419-22.
67. Extermann M. Measuring comorbidity in older cancer patients. Eur J Cancer. 2000;36:453-71.
68. Robinson JK, Altman JS, Rademaker AW. Socioeconomic status and attitudes of 51 patients with giant basal and squamous cell carcinoma and paired controls. Arch Dermatol. 1995;131:428-31.
69. Chuang TY. Skin cancer II: non melanoma skin cancer. In: The challenge of dermato-epidemiology. Boca Raton, FL: CRC, 1997, pp. 209-22.
70. Housman TS, Feldman SR, Williford PM, Fleischer AB Jr, Goldman ND, Acostamadiedo JM, Chen GJ. Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol. 2003;48:425-9.
71. John Chen G, Yelverton CB, Polisetty SS, Housman TS, Williford PM, Teuschler HV, Feldman SR. Treatment patterns and cost of nonmelanoma skin cancer management. Dermatol Surg. 2006;32:1266-71.
72. Chren MM, Sahay AP, Bertenthal DS, Sen S, Landefeld CS. Quality-of-life outcomes of treatments for cutaneous basal cell carcinoma and squamous cell carcinoma. J Invest Dermatol. 2007;127:1351-7.
73. Rhee JS, Matthews BA, Neuburg M, Logan BR, Burzynski M, Nattinger AB. The skin cancer index: clinical responsiveness and predictors of quality of life. Laryngoscope. 2007;117:399-405.
74. Rhee JS, Matthews BA, Neuburg M, Smith TL, Burzynski M, Nattinger AB. Quality of life and sun-protective behavior in patients with skin cancer. Arch Otolaryngol Head Neck Surg. 2004;130:141-6.